| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
It is needed for development of novel therapeutic strategy based on autophagy activity in tumor from individual patients for cancer therapy. In this study, we found that 1) high expression of p62 protein, an autophagic substrate, may be a possible biomarker for autophagy-impaired cancers, 2) miR-634 has a tumor-suppressive function by concurrently targeting multiple cytoprotective processes including autophagy, 3) autophagy inhibition leads to an increased sensitivity to L-asparaginase in acute lymphoblastic leukemia (ALL). These findings provide novel insight for development of novel therapeutic strategy based on autophagy activity for cancer therapy.
|
